ART in rural Uganda-efficient scale-up with home-based care?

The Lancet

Volumn 374, Issue 9707, 2009, Pages 2034-2035

  Korenromp, Eline L ^a,b   Viisainen, Kirsi M ^a  

^a TUBERCULOSIS AND MALARIA   (Switzerland)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRAL THERAPY; ARTICLE; CLINICAL RESEARCH; COUNSELING; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE FACILITY; HEALTH CARE ORGANIZATION; HEALTH PROGRAM; HEALTH SERVICE; HOME CARE; HUMAN; PRIORITY JOURNAL; RURAL AREA; UGANDA;

EID: 72149088740     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)62027-4     Document Type: Note

References (13)

1. Jaffar S., Amuron B., Foster S., et al., on behalf of the Jinja trial team. Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial. Lancet (2009) 10.1016/S0140-6736(09)61674-3 published online Nov 24.
2. Gilks C., and Vitoria M. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach (2006). http://www.who.int/hiv/pub/guidelines/artadultguidelines.pdf (accessed Nov 17, 2009).
3. The Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration and ART Cohort Collaboration (ART-CC) groups. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 367 (2006) 817-824
4. Amuron B., Namara G., Birungi J., et al. Mortality and loss-to-follow-up during the pre-treatment period in an antiretroviral therapy programme under normal health service conditions in Uganda. BMC Public Health 9 (2009) 290
5. Lawn S.D., Myer L., Harling G., et al. Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation. Clin Infect Dis 43 (2006) 770-776
6. Koenig S.P., Riviere C., Leger P., et al. The cost of antiretroviral therapy in Haiti. Cost Eff Resour Alloc 6 (2008) 3
7. Cleary S.M., McIntyre D., and Boulle A.M. The cost-effectiveness of antiretroviral treatment in Khayelitsha, South Africa-a primary data analysis. Cost Effect Resour Alloc 4 (2006) 20
8. WHO, UNAIDS, UNICEF. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector (2009). http://www.who.int/hiv/pub/2009progressreport/en (accessed Nov 17, 2009).
9. UNAIDS, World Bank Global HIV/AIDS program. The global economic crisis and HIV prevention and treatment programmes: vulnerabilities and impact (2009). http://data.unaids.org/pub/Report/2009/jc1734_econ_crisis_hiv_response_e n.pdf (accessed Nov 17, 2009).
10. UNAIDS. What countries need: investments needed for 2010 targets (2009). http://data.unaids.org/pub/Report/2009/JC1681_what_countries_need_en.pdf (accessed Nov 17, 2009).
11. Global Fund to Fight AIDS, Tuberculosis and Malaria. Value for money for Global Fund-supported health programs (2009). http://www.theglobalfund.org/en/performance/effectiveness/value/?lang=en (accessed Nov 17, 2009).
12. United States Presidential Emergency Plan for AIDS Relief (PEPFAR). An act to authorize appropriations for fiscal years 2009 through 2013 to provide assistance to foreign countries to combat HIV/AIDS, tuberculosis, and malaria, and for other purposes (2009). http://www.pepfar.gov/documents/organization/108294.pdf (accessed Nov 17, 2009).
13. United Kingdom Department for International Development. Achieving universal access-the UK's strategy for halting and reversing the spread of HIV in the developing world. Monitoring performance and evaluating impact (2009). http://www.dfid.gov.uk/Documents/publications/achving-uni-access-mon-eva l.pdf (accessed Nov 17, 2009).